At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. - Wikidata - wikimedia - TriplyDB

At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia.

At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia.

http://www.wikidata.org/entity/Q51808997

about

Dopamine-prolactin pathway potentially contributes to the schizophrenia and type 2 diabetes comorbidity Etiology of cardiovascular disease in patients with schizophrenia: current perspectives Obesity and psychotic disorders: uncovering common mechanisms through metabolomics Pharmacogenomics in type 2 diabetes: oral antidiabetic drugs.The ventral habenulae of zebrafish develop in prosomere 2 dependent on Tcf7l2 function.Using genetic, cognitive and multi-modal neuroimaging data to identify ultra-high-risk and first-episode psychosis at the individual level.TCF7L2 polymorphisms and the risk of schizophrenia in the Chinese Han population Bayesian semiparametric copula estimation with application to psychiatric genetics Modulation ofTcf7l2 expression alters behavior in mice.Association of the type 2 diabetes mellitus susceptibility gene, TCF7L2, with schizophrenia in an Arab-Israeli family sample Translational neuroscience of schizophrenia: seeking a meeting of minds between mouse and man.An in vivo cis-regulatory screen at the type 2 diabetes associated TCF7L2 locus identifies multiple tissue-specific enhancers.Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors.Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits.Novel β-catenin target genes identified in thalamic neurons encode modulators of neuronal excitability.Excess mortality, causes of death and life expectancy in 270,770 patients with recent onset of mental disorders in Denmark, Finland and Sweden.Wnt signaling and the control of human stem cell fate.Microarray Analysis of Human Blood During Electroconvulsive Therapy.Clinicians' adherence to clinical practice guidelines for cardiac function monitoring during antipsychotic treatment: a retrospective report on 434 patients with severe mental illness.Cell type-specific binding patterns reveal that TCF7L2 can be tethered to the genome by association with GATA3.Interventions for the metabolic syndrome in schizophrenia: a review Polygenic risk for type 2 diabetes mellitus among individuals with psychosis and their relatives.The prevalence and mechanisms of metabolic syndrome in schizophrenia: a review.Metabolic syndrome in schizophrenia: theoretical, clinical and translational perspectives.Postnatal isoform switch and protein localization of LEF1 and TCF7L2 transcription factors in cortical, thalamic, and mesencephalic regions of the adult mouse brain.Preliminary evidence for a role of the adrenergic nervous system in generalized anxiety disorder.Metabolic profile at first-time schizophrenia diagnosis: a population-based cross-sectional study.TNiK is required for postsynaptic and nuclear signaling pathways and cognitive function TCF4 (e2-2; ITF2): a schizophrenia-associated gene with pleiotropic effects on human disease.Physiological role of β-catenin/TCF signaling in neurons of the adult brain.Running for your life: A review of physical activity and cardiovascular disease risk reduction in individuals with schizophrenia.Diabetes and Schizophrenia.Screening of cardiovascular risk factors in patients with schizophrenia and patients treated with antipsychotic drugs: are we equally exhaustive as with the general population?In vitro scan for enhancers at the TCF7L2 locus.Psychiatric disorders and obesity: A review of association studies Genetic Background Limits Generalizability of Genotype-Phenotype Relationships.Diabetes, physical activity participation and exercise capacity in patients with schizophrenia.Genetic association study between the detected risk variants based upon type II diabetes GWAS and psychotic disorders in the Japanese population.A polygenic score for schizophrenia predicts glycemic control.Accumulating evidence for a role of TCF7L2 variants in bipolar disorder with elevated body mass index.

P2860

Q26752342-8A3DA169-68CA-430F-A210-343D4359F042 Q26778485-D7D6A371-390E-4BDB-B72A-3E9E64F3E5C8 Q27011617-419597DD-EE83-4BB5-9434-2850B0521C45 Q30248914-4ECBE917-F61F-4F1C-8026-092748A0EA71 Q30557277-649F063C-F77B-4EB1-92C2-CE634AAAAF05 Q30603105-CB9DF6B5-9C6D-43FD-BE46-91AD9D5741EA Q33709807-2F8EBE26-A52F-4C27-B87E-89D7DBCF8225 Q33867602-B865DF03-C5E7-46D6-B0CE-94014C2722BB Q34064796-D2EC6EBB-F0BB-4D45-845B-E67C946A3E0C Q34128452-3CC92C6A-433D-4F4A-88CD-D6E66F0722DF Q34220141-AC152347-42C1-4621-9BF7-63EB2CD38076 Q34270782-4BC25F52-D063-426E-BF32-0C43A2DAB7FC Q34325802-9D01518D-9F25-408E-BA06-3223D32F68FE Q34379379-587D0496-EDAE-45D8-A778-90A74D6C00CA Q34479682-69549814-2E8A-420F-AEA7-FB61DBC1015E Q34571634-FB922B42-4161-49B7-9DCA-C36949D744B9 Q34658275-08ACFFEF-4F32-4BA1-9778-E0C6EACA1360 Q36298817-A75E2CDA-AC5D-4C51-9358-04F7E1ACD5A2 Q36328767-0D75DE29-874B-4E9B-9119-F55B534C67A6 Q36378040-1922B43B-39DB-476A-9B2F-581AA355FFEF Q36401248-DDE8A6F8-50F3-4B39-B273-804198F95E39 Q36784390-9E222E3A-429C-43E4-86FA-313B2288E7A0 Q37079080-2B98DFBE-2576-44EB-B50A-F89EB1B2C104 Q37176819-8C161D17-6F43-4118-94EE-88F8C669CA1D Q37301034-16B33D97-0578-43F5-AD37-07A48E320DC2 Q37642812-A5A4D9CF-39ED-4C8D-B8E0-543FE16D90D8 Q37682840-34DECADA-DA20-4532-8BB8-406D209EBB8B Q37690413-5F6EE4D5-A8FC-42E4-A843-07D5A74EACA3 Q38057999-291E4C14-1080-48BE-B2B1-0F31B72D049D Q38078834-F19EFAE5-F125-4454-8589-779B30A9B3C1 Q38656912-F8CF1600-5ABF-4A9C-8475-806C58810654 Q38709352-0CB9CB87-B5D2-4EE9-8165-1B4E2BE4843B Q38738796-99813241-9ADA-4506-A4B5-478191309B44 Q39271500-7D7A75CE-AD97-40D9-B9DE-4F3AA2BE89A7 Q39427970-501DD9C2-E013-4341-B4E9-18EE984A36A0 Q41159260-5E7DAE89-4454-4618-9D4F-C5BE106259F2 Q46197558-26D5316A-74BA-4C4E-B9FB-799D37BA17C8 Q46884539-E3D1104B-5DE7-45D4-89E1-0E65E370C537 Q47294911-0D75D2E7-C080-459D-9F67-ECDF3FD37A02 Q47629882-818AED92-8CDB-4538-B35D-EF88A8ECFF97

P2860

At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia.

http://www.wikidata.org/entity/Q51808997

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia.

@en

At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia.

@nl

type

label

At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia.

@en

At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia.

@nl

prefLabel

At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia.

@en

At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia.

@nl

P1433

Q51808997-3D7E61EB-86E2-42A1-B9A4-C025C87A5F07

P1476

Q51808997-DAAF1DEE-D3FB-45EA-86F6-7C76EE046B5A

P2093

Q51808997-01EE15F1-6FDC-41D8-B83C-D60D23957400

Q51808997-0372A634-C30A-4AEA-9246-FE0EBF81584C

Q51808997-038E13AF-1FE4-4D5C-9508-60BFFB9CD824

Q51808997-098219B9-8571-4ACC-B2FE-E294F3A51DC4

Q51808997-13A5CE40-E107-4D3B-B70E-5C1246EDD98A

Q51808997-2F0E3B73-C635-408C-AC4F-008A683EBBC0

Q51808997-4FA9C3CB-08B9-47EB-9278-B1955E363651

Q51808997-5F8913B5-8883-4C25-96FE-AF68E2353976

Q51808997-71E8C997-2D93-43CF-9579-1B183BA70378

Q51808997-790FF128-F698-49D8-8D45-6AE4FE8E665C

P304

Q51808997-6358BBD7-C98C-4C2E-9AFC-76F3D6EBEDEA

P31

Q51808997-0CC69D1C-B499-40DC-B825-46C097BFB350

P356

Q51808997-B43103F2-EB4A-4EA6-9C0F-B1D9B9D518B9

P407

Q51808997-A86B0D6F-DCEB-4BD6-9FBF-4DAA1910BB75

P433

Q51808997-6846E6E4-57B4-4B86-A219-1C8E3ADD70CE

P478

Q51808997-94B80EB4-549E-442E-B9F8-CB19075CD545

P50

Q51808997-11C22574-9DD1-47CA-AD36-B900AE11C3E0

Q51808997-3A28E973-A5E8-4150-A5C0-E5A97C2C9D87

Q51808997-3F2CA4EB-EE6F-4FE1-AD72-8BAC569AEA80

Q51808997-54721CA3-9ED3-4B92-8AED-86B14CFDF0C3

Q51808997-54D5597B-7F41-4BF0-8A5B-E97BACE5A271

Q51808997-69A27DAB-A684-43A1-A33D-0CCEBE2D9ADA

Q51808997-7D7034CA-D89A-4DE0-B924-9E2D941EF012

Q51808997-98002D5D-7E17-41D3-BFE1-7F32FD3AD4AE

Q51808997-99A6C3FF-B61E-4D34-BC25-DE4D6E949B21

Q51808997-B56A75F4-7C0E-4A6C-B540-6D0F247CF02A

P577

Q51808997-6D0611DE-5E6A-489D-954D-B0F751816B47

P698

Q51808997-6D899A12-0DAD-4EFF-B561-F1A32E83D97B

P921

Q51808997-0C8D9284-3BCD-4845-A2EF-BF953AF5B5A6

Q51808997-A6F8B024-7D59-4410-9323-7A9B3D334D15

P356

J.BIOPSYCH.2011.01.031

P1433

Biological Psychiatry

P1476

At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia.

@en

P2093

Andrés Ingason

http://www.w3.org/2001/XMLSchema#string

Chiara Bonetto

http://www.w3.org/2001/XMLSchema#string

David A Collier

http://www.w3.org/2001/XMLSchema#string

David St Clair

http://www.w3.org/2001/XMLSchema#string

Hannes Pétursson

http://www.w3.org/2001/XMLSchema#string

Henrik B Rasmussen

http://www.w3.org/2001/XMLSchema#string

Josef Frank

http://www.w3.org/2001/XMLSchema#string

Klaus D Jakobsen

http://www.w3.org/2001/XMLSchema#string

Leena Peltonen

http://www.w3.org/2001/XMLSchema#string

Mike Owen

http://www.w3.org/2001/XMLSchema#string

P304

59-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.BIOPSYCH.2011.01.031

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

70

http://www.w3.org/2001/XMLSchema#string

P50

Marcella Rietschel

Jouko Lönnqvist

Michael C O'Donovan

Ole A. Andreassen

Srdjan Djurovic

Markus M Nöthen

Thomas F. Hansen

P577

2011-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21414605

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes